SCHEMBL723151

SCHEMBL723151

CC(C)(OC(N)=O)c1ccccc1N=Nc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RAB9A P51151 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
PPARA Q07869 5/20 0.38
IDE P14735 1/20 0.38
MYC P01106 1/20 0.38
TRPA1 O75762 1/20 0.38
KMT2A Q03164 4/20 0.37
NPC1 O15118 3/20 0.37
MEN1 O00255 3/20 0.37
MAPK1 P28482 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 1/20 0.36
SUMO2 P61956 1/20 0.36
SUMO1 P63165 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15643677 1.00 MAPT (0.40) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL530698 0.84 KCNN4 (0.38) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL155459 0.80 MAPT (0.46) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL27935083 0.80 MAPT (0.49) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL113257 0.80 MAPT (0.46) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL29763577 0.79 MAPT (0.42) MAPTL3MBTL1KMT2AMEN1MAPK1
SCHEMBL10415826 0.73 ALDH1A1 (0.50) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL28556998 0.73 CYP2D6 (0.51) MAPTL3MBTL1RAB9ASENP7CASP3
SCHEMBL7185639 0.73 ALDH1A1 (0.43) MAPTMYCKMT2ATDP1SMN1; SMN2
SCHEMBL4287836 0.73 GABRA1 (0.37) MAPTRAB9AMYCKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064769-A1 INDUCTION OF STEM-LIKE ACTIVATED T CELLS PHIO PHARMACEUTICALS CORP. (US) 2024-03-28 WO disclosed
US-20230416283-A1 CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-12-28 US disclosed
EP-3775203-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF Wave Life Sciences Ltd. (SG) 2021-02-17 EP disclosed
EP-3645600-A1 CORE-TO-SURFACE POLYMERIZATION FOR THE SYNTHESIS OF STAR POLYMERS AND USES THEREOF Massachusetts Institute of Technology (US) 2020-05-06 EP disclosed
US-10633407-B2 14-membered ketolides and methods of their preparation and use PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-04-28 US disclosed
WO-2019200185-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2019-10-17 WO disclosed
EP-3544971-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2019-10-02 EP disclosed
WO-2019032961-A1 TRIOXACARCIN-ANTIBODY CONJUGATES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-02-14 WO disclosed
WO-2019006425-A1 BRUSH-ARM STAR POLYMER IMAGING AGENTS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-03 WO disclosed
WO-2019006422-A1 CORE-TO-SURFACE POLYMERIZATION FOR THE SYNTHESIS OF STAR POLYMERS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-03 WO disclosed
US-9080171-B2 Reduced size self-delivering RNAi compounds RXi Parmaceuticals Corporation (US) 2015-07-14 US disclosed
EP-2791128-A1 NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF Olema Pharmaceuticals, Inc. (US) 2014-10-22 EP disclosed
WO-2014160441-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF SAGE THERAPEUTICS, INC. (US) 2014-10-02 WO disclosed
US-20140113950-A1 INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS RXI PHARMACEUTICALS CORPORATION (US) 2014-04-24 US disclosed
WO-2013090921-A1 NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF OLEMA PHARMACEUTICALS, INC. (US) 2013-06-20 WO disclosed
WO-2012027555-A2 GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-01 WO disclosed
EP-2348845-A1 ANSAMYCIN HYDROQUINONE COMPOSITIONS Infinity Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
EP-2337809-A1 POLYCARBONATE POLYOL COMPOSITIONS AND METHODS Novomer, Inc. (US) 2011-06-29 EP disclosed
WO-2010045442-A1 ANSAMYCIN HYDROQUINONE COMPOSITIONS INFINITY DISCOVERY, INC. (US) 2010-04-22 WO disclosed
WO-2010028362-A1 POLYCARBONATE POLYOL COMPOSITIONS AND METHODS NOVOMER, INC. (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416283-A1 CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS PGD, CDCA2, MCM2 MAPT 684/4885L3MBTL1 3620/4885RAB9A 3389/4885
US-10633407-B2 14-membered ketolides and methods of their preparation and use CYP51A1, HSD17B7, CYP11B1 MAPT 2547/4885L3MBTL1 3210/4885RAB9A 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.